What is XFOR's current stock price?

XFOR (X4 Pharmaceuticals, Inc.) is currently trading at $4.04 with a market cap of $46.1M.

What sector is X4 Pharmaceuticals, Inc. in?

X4 Pharmaceuticals, Inc. (XFOR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is XFOR a good stock to buy?

Analysts have a Buy consensus on XFOR with a price target of $11.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

XFOR X4 Pharmaceuticals, Inc.

Healthcare

$4.04+0.00%ClosedMarket Cap: $46.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.03

P/S

5.11

EV/EBITDA

1.76

DCF Value

$22.51

FCF Yield

-158.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

79.4%

Operating Margin

-1084.4%

Net Margin

-1106.3%

ROE

-94.9%

ROA

-36.9%

ROIC

-39.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$2.7M	$-20.2M	$—
Q4 null	$2.6M	$-23.9M	$—
FY null	$35.1M	$-79.2M	$—
Q3 null	$1.8M	$-29.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$11.00

Target (Median)

$11.00

Target Range

$10.00 - $12.00

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

StifelBuy

2025-12-05

HC Wainwright & Co.Buy

2025-11-10

StifelBuy

2025-08-29

HC Wainwright & Co.Buy

2025-08-13

Trading Activity

Insider Trades

View All

KIRSKE DAVIDofficer: Chief Financial Officer

SellWed May 13

Bridger Garydirector

SellWed Jan 07

WYZGA MICHAEL Sdirector

SellMon Jan 05

Stewart Murraydirector

SellMon Jan 05

de Craecker Francoisedirector

SellMon Jan 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.32

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Peers

KZR